Greenwich Lifesciences Provides Clinical Trial and Pipeline Update

Company's ATM financing strategy and progress on Phase III breast cancer trial FLAMINGO-01

Apr. 14, 2026 at 5:08pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray photograph revealing the internal structures of a human breast, conceptually representing the clinical progress of a new cancer immunotherapy.Greenwich LifeSciences' innovative breast cancer immunotherapy aims to harness the body's own defenses to fight high-risk HER2-positive tumors.Houston Today

Greenwich LifeSciences, Inc. provided updates on its financing strategy and progress of its Phase III clinical trial FLAMINGO-01 evaluating the safety and efficacy of its breast cancer immunotherapy candidate GLSI-100. The company's ATM financing vehicle allowed it to raise funds exceeding its Q1 2026 cash burn rate, resulting in a cash balance of $10.5 million. FLAMINGO-01 has now fully enrolled the 250-patient non-HLA-A*02 arm, with preliminary data showing a 70-80% reduction in recurrence rate, similar to the previous Phase IIb trial results.

Why it matters

Greenwich LifeSciences is developing a potentially groundbreaking breast cancer immunotherapy that could significantly improve outcomes for patients, especially those with high-risk HER2-positive disease. The progress on the FLAMINGO-01 trial and the company's financing strategy are important milestones that could pave the way for the therapy's advancement and eventual regulatory approval.

The details

Greenwich LifeSciences' ATM financing vehicle allowed the company to raise funds exceeding its Q1 2026 cash burn rate, resulting in a cash balance of $10.5 million as of March 31, 2026. The company's Phase III FLAMINGO-01 trial has now fully enrolled the 250-patient non-HLA-A*02 arm, where all patients received the GLSI-100 immunotherapy. Preliminary analysis of this arm shows an approximately 70-80% reduction in recurrence rate, similar to the 80% reduction seen in the HLA-A*02 patients treated in the previous Phase IIb trial. The trial is designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, with an interim analysis planned when at least 14 events have occurred.

  • Greenwich LifeSciences reported its Q1 2026 financial results on April 14, 2026.
  • The FLAMINGO-01 Phase III trial is currently ongoing, with plans to open up to 150 sites globally.

The players

Greenwich LifeSciences, Inc.

A clinical-stage biopharmaceutical company developing a novel cancer immunotherapy for breast cancer.

FLAMINGO-01

A Phase III clinical trial designed to evaluate the safety and efficacy of Greenwich LifeSciences' GLSI-100 immunotherapy in HER2-positive breast cancer patients.

Baylor College of Medicine

The lead institution overseeing the FLAMINGO-01 Phase III trial.

Got photos? Submit your photos here. ›

What’s next

An interim analysis for superiority and futility will be conducted when at least half of the required 28 events, 14, have occurred in the FLAMINGO-01 Phase III trial.

The takeaway

Greenwich LifeSciences' progress on its FLAMINGO-01 Phase III trial and its successful financing strategy position the company well to potentially bring its innovative breast cancer immunotherapy to market, offering new hope for patients with high-risk HER2-positive disease.